This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.
This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... However, BMS is facing competition from generic rivals of Eliquis – in December 2019, the FDA approved
The positive quarterly results build on BMS’ key patent challenge victory on Wednesday for its blood thinner Eliquis (apixaban). ... Eliquis was the second biggest seller in the second quarter, bringing in $4.8bn.
BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to
ago. Meanwhile, vaccine blockbuster Prevnar also continued its slowdown, but still brought in $1.58bn in the quarter, and anticoagulant Eliquis (apixaban) continued its strong growth with a 21% gain to
Sets stage for lower-cost competition to big-selling drug. The FDA has approved the first two generics of Pfizer and Bristol-Myers Squibb’s blockbuster anticoagulant drug Eliquis, from Micro ... The two companies have been actively challenging attempts
Anticoagulant Eliquis (apixaban) did better than predicted with a 22% increase to $1.93bn, and there were also solid gains for arthritis and psoriasis therapy Orencia (abatacept) – up 14% to $767m –
More from news
Approximately 15 fully matching, plus 79 partially matching documents found.
Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others.
This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.
Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...